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INTRODUCTION
Vitamin B12 is an enzyme co-factor in two pathways in 
humans, namely (i) the regeneration of methionine from 
homocysteine in the cytoplasm, and (ii) the re-arrangement 
of methylmalonic acid (MMA)-Coenzyme A (CoA) to 
succinyl-CoA in the mitochondria. These reactions support 
DNA synthesis and lipid metabolism, and also detoxify the 
substrates homocysteine and MMA. Low-serum vitamin 
B12 levels have been associated with cognitive decline in 
Alzheimer’s disease (AD) [1], Parkinson’s disease [2], and 
vascular dementia [3].
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ABSTRACT
Objective: Vitamin B12 deficiency is common in older adults, and may increase the risk of cognitive impairment. 
The distribution of vitamin B12 insufficiency in younger age groups is less studied. This study aims to assess 
the prevalence of vitamin B12 deficiency (<156 ρmol/L) and subclinical low-normal levels (156-250 ρmol/L) 
in a large, random sample of the Australian population across the adult life span. Methods: We examined 
serum vitamin B12 levels in a random sample of 1085 men and 1125 women aged 20-97 years between 1994 
and 2006; in the Barwon statistical division, a regional area in southeastern Australia that is representative of 
the socioeconomic status of the Australian population. Results: The age-standardized prevalence of vitamin 
B12 deficiency in this cohort of men and women was 3.6%. Subclinical low-normal vitamin B12 levels (156-250 ρmol/L) were found in 26%. Serum vitamin B12 levels declined with age among men (P < 0.001) and were lower 
in men than women (P < 0.001). Vitamin B12 levels were higher among supplements users (8.0% of the cohort). 
Conclusions: Vitamin B12 levels decline with age, and have been associated with neurodegenerative diseases 
and cognitive decline. Early intervention by diet education or supplement use to address this age-associated 
decline in vitamin levels may be an effective strategy to prevent cognitive decline in a significant segment 
of the population. Such intervention may need to start in mid-life (from 50-years of age) before the onset of 
age-related decline in vitamin B12 levels.
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The lower reference value for serum vitamin B12 varies 
with each method of assay and population sampled, but 
approximates to 150 ρmol/L. Metabolic abnormalities, such 
as elevated homocysteine or MMA levels, altered deoxyuridine 
suppression, or hematological changes frequently occur 
with low-normal B12 levels (~150-250 ρmol/L) [4]. 
Laboratory indicators of vitamin B12 deficiency, including 
hyperhomocysteinemia, neutrophil hypersegmentation, and 
macrocytosis may also be seen at vitamin B12 concentrations 
up to 250 ρmol/L [5]. In addition, serum vitamin B12 
levels < 308 ρmol/L were associated with increased brain 
atrophy in a survey of 107 over-60 year olds [6]. The findings 
are of particularly concern for the ageing population as 
the conditions causing low vitamin B12 levels occur more 
frequently with increasing age.
Vitamin B12 is obtained from sea-food, animal products, eggs and 
dairy, but is lacking from strict vegetarian diets. Older adults may 
consume less animal source foods due to an inability to prepare 
meals, poor teeth, or reduced income. A number of conditions 
can disrupt absorption of vitamin B12 in older adults despite 
adequate dietary intake:
• Infection with Helicobacter pylori was associated with lower 
serum vitamin B12 and an increased risk of deficiency [7],• Proton pump inhibitor (PPI) use for more than 12 months 
significantly increased the risk of developing vitamin B12 
deficiency (odds ratio 4.45; 95% confidence interval [CI]: 
1.47-13.34) in those aged 65 years or older [8],
• Pernicious anemia, an autoimmune reaction to intrinsic 
factor or the parietal cells, experienced by 15% of vitamin 
B12 deficient over-65 year olds [7],• An interaction between the cubilin receptor and the 
anti-diabetic drug metformin inhibits adequate uptake in 
up to 30% of metformin users [9],
• Resection or disease of the absorbing surface at the distal 
ileum.
Previous Australian studies of vitamin B12 deficiency have been 
in selected populations. Vitamin B12 levels < 185 ρmol/L were 
seen in 22.9% of participants in the study of 2901 over-50 year 
olds in Sydney [10]. In a study of 299 over-75 year olds in Perth, 
55% had low-vitamin B12 levels (<258 ρmol/L) [11]. Elevated 
homocysteine level is a non-specific marker for vitamin B12 
deficiency. Homocysteine levels were elevated in 24% of men 
and women aged 70 years and older in Perth [12].
It is unclear from these previous studies whether low-normal 
vitamin B12 levels (up to 250 ρmol/L) are common in younger 
adult Australians, or are a feature of ageing. In the Australian 
population, low vitamin B12 levels was reported to increase the 
risk of cognitive impairment, and this risk was exacerbated 
when folate levels were high[13] and also amongst patients with 
diabetes who used metformin [14].
We studied the prevalence of vitamin B12 deficiency and 
subclinical low-normal vitamin B12 levels in a population-based, 
random sample of Australian men and women aged 20-years 
and older. The efficacy of commercially-available supplements 
to prevent or treat low-normal vitamin B12 levels was assessed.
METHODS
Participants and Setting
An age-stratified random sample (n = 3,034) was drawn from 
the commonwealth electoral rolls for the region defined as the 
Barwon statistical division in Victoria, Australia [15]. This 
sample was drawn initially to investigate the epidemiology 
of osteoporosis in Australian women as part of the Geelong 
osteoporosis study (GOS). Data generated on this cohort 
was used to establish the reference ranges used in bone 
densitometers in Australia, initially for women [16], and later 
for men [17].
Fasting serum samples were obtained between 1994 and 
1997 from 1,244 women (mean age, 52.6 years; range 
20.3-93.1 years), and between 2001 and 2006 from 1133 
men (mean age, 59.8 years; range 20.7-96.7 years). Serum 
vitamin B12 assays were performed in the same laboratory using 
the same instrumentation and type of assay, for the duration 
of the study. A number of participants did not have samples 
taken for vitamin B12 measurement (n = 657). A further 165 
participants did not adequately complete questionnaires, 
so were excluded. The final response fraction was 72.9%, 
which included 176 participants who reported using vitamin 
B12 supplements, and 2034 participants who did not use 
vitamin B12 supplements.
Ethical Approval
This study was approved by the Barwon Health Human Research 
Ethics Committee, under reference number 09/12. Written, 
informed consent was obtained from all participants.
Self-Reported Questionnaires
Details of all medications used and of all current and past 
medical conditions were self-reported by participants and were 
documented by questionnaire. Participants were asked to record 
both current and previous use of supplements and to define 
the usage period, as well as the route of administration. The 
supplements used were those typically available over-the-counter. 
Vitamin B12 supplement use included multi-vitamins and 
low-dose formulations.
Biochemical Analysis
Blood samples were collected after an overnight fast and 
were centrifuged, separated and stored at-80°C. Serum 
concentrations of vitamin B12 were determined using 
the Roche vitamin B12 reagent kit (Roche Diagnostics, 
Mannheim, Germany) on a Roche modular analytics E170 
analyzer (Electro-Chemiluminescence Immunoassay) with 
inter-assay precision of 5.9% at 183.7 ρmol/L, 5.6% at 427.4 
ρmol/L, and 4.8% at 779.2 ρmol/L. The lower reference 
value for this assay was 156 ρmol/L. The vitamin B12 analyses 
were performed in the Alfred pathology service, clinical 
biochemistry unit.
J Invest Biochem ● 2014 ● Vol 3 ● Issue 3  97
Moore, et al.: Vitamin B12 defi ciency in Australia
Statistical Analysis
The vitamin B12 levels of supplement user-and non-supplement 
user-groups, and between men and women, were compared 
using the Mann–Whitney test. A linear regression model was 
formed to investigate the association between serum vitamin 
B12 levels (response) and supplement use (predictor), with age 
and gender as adjusters. Differences at the P = 0.05 level were 
considered significant. Age-standardized estimates for the 
prevalence of deficiency and of subclinical low-normal vitamin 
B12 levels in the Australian population were derived using the 2006 
census data collected by the Australian Bureau of Statistics [18]. All 
statistical analyses were performed using  Minitab® Version 15.1.1.0 
(Minitab Inc., Pennsylvania State College, Pennsylvania, USA).
RESULTS
The Prevalence of Deficiency and Subclinical 
Low-normal Serum Vitamin B12 Levels
One hundred and five participants had serum vitamin 
B12 level in the deficient range (<156 ρmol/L). The 
age-standardized prevalence of deficiency in the whole 
cohort was 3.6% (95% CI: 3.0-4.8%). Vitamin B12 deficiency 
was rarer in those under the age of 50 years (2.2%); whereas 
5.2% (95% CI: 4.2-6.9%) of over 50 years old were deficient. This 
number increased to 8.5% (95% CI: 6.9-11.3%) in over 65 years 
old. The age-standardized prevalence of low-normal vitamin B12 
levels (156-250 ρmol/L) was 25.8% [Table 1].
Vitamin B12 Supplements Improve Serum Vitamin B12 
Levels
The median serum vitamin B12 levels of 176 participants who 
were on vitamin B12 supplements were 36% higher than other 
participants (Mann–Whitney test, P < 0.001). The median for 
supplement users was 404 ρmol/L, with range 158 to > 1476 
ρmol/L; whereas, the median for participants who did not 
use supplements was 297 ρmol/L, with range 66-777 ρmol/L. 
Ten-supplement users (5.7%) had serum vitamin B12 level of 
1476 ρmol/L or greater. This is the upper limit of quantitation 
for the instrument used. Supplement use was a significant 
predictor of vitamin B12 levels after adjusting for both gender 
and age (P < 0.001). None of the supplement users had deficient 
serum vitamin B12 levels. Thirteen percent of supplement users 
had subclinical low-normal serum vitamin B12 levels. There were 
proportionally more women who took vitamin B12 supplements 
than men (10.8% vs. 6.5%, P = 0.002). Only five participants 
received intramuscular vitamin B12 injections, so there were 
insufficient numbers to compare between supplementation types.
Gender and Age Charts for Serum Vitamin B12 Levels 
in the Barwon Statistical Division
Among participants who did not use supplements, serum 
vitamin B12 levels were lower in men than women (age-adjusted, 
P < 0.001). The median for men was 284 ρmol/L (range 129-564 
ρmol/L); whereas the median for women was 308 ρmol/L (range 
142-632 ρmol/L). There was a decline of vitamin B12 levels with 
age in males but not in females [Figure 1].
Table 1: Characteristics of cohort
Characteristics of cohort Males Females Whole 
cohort
Total number of participants 1085 1125 2210
Number of vitamin B12 supplement users (%) 66 (6.1) 110 (9.8) 176 (8.0)
Total number of participants who did not 
use supplements
1019 1015 2034
Observed prevalences in participants who 
did not use supplements
Deficient (vitamin B12<156 ρmol/L) % 6.3 4.0 5.2
Subclinical low-normal levels (vitamin 
B12: 156-250 ρmol/L) %
32.2 24.0 28.1
Age-standardized prevalences in 
participants who did not use supplementsa
Deficient (vitamin B12<156 ρmol/L) % 3.6 3.0 3.6
Subclinical low-normal levels (vitamin 
B12: 156-250 ρmol/L) (%)
28.4 23.4 25.8
aAge-standardized values have been derived using the 2006 census data 
collected by the Australian Bureau of Statistics [19]
Figure 1: Age stratifi ed serum vitamin B12 levels of men and women across the adult lifespan. Box-and-whisker charts showing the median (line 
inside box), inter-quartile range (boxed region), and the 2.5th and 97.5th centiles for vitamin B12 levels. The marked regions indicate the ranges for 
defi ciency (<156 ρmol/L) and subclinical low-normal levels (156-250 ρmol/L). Results for males are shaded, results for females are not shaded
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Excluded Patients were Older and Included a Higher 
Proportion of Men
In total, 822 participants originally recruited to the GOS 
study (27.1%) were not included in this investigation of vitamin 
B12 levels. The proportion of vitamin B12 supplement users in 
the excluded group was not different to that in the included 
group (7.4% vs. 8.0%, Chi-square, P = 0.6753). The excluded group 
were older (mean difference 2.4 years, P = 0.004) and included a 
higher proportion of men (55% vs. 49%, P < 0.004). Age and gender 
standardization of our prevalence data would counteract the lower 
response fraction, increasing confidence in the results obtained.
DISCUSSION
In our cohort, the age-standardized prevalence of deficiency was 
3.6%. This is consistent with other data from older studies using 
strict definitions of pernicious anemia [20]. The serum vitamin B12 
levels of just over one-quarter of our cohort were in the subclinical 
low-normal range (156-250 ρmol/L). Furthermore, 54% of males 
aged 80 years or over had a serum vitamin B12 level < 250 ρmol/L. 
Our findings in this age group are similar to figures reported 
earlier in Australia [10], and in other countries, with deficiency in 
over 50 years old of 5.2% and subclinical low-normal levels in 28.5%.
The majority of studies investigating the prevalence of deficiency 
and subclinical low-normal values have been conducted in 
older adults. Table 2 compares our findings with those from a 
Sydney study, and other countries, showing a similar prevalence 
of deficiency in the Australian population to the USA [18], 
Israel [21], and Finland [22]. Subclinical low-normal serum 
vitamin B12 levels are high in each of the older populations 
surveyed, and range from 24.0% to 35.3%. For comparison, only 
data from over 50 years old in the GOS cohort is shown in Table 2.
The clinical reference value used to define vitamin B12 deficiency 
was that provided by the assay kit manufacturer (<156 ρmol/L; 
Roche Diagnostics, Mannheim, Germany). This value was 
originally derived from a survey of 178 healthy US adults 
with no signs of vitamin B12 deficiency. Recently, attention 
was drawn to the failure of vitamin B12 assays to identify 
patients with pernicious anemia which will respond to 
B12 supplementation [25]. The presence of anti-intrinsic factor 
antibodies may interfere with competitive-binding assays 
that are currently available, such that false-normal or even 
very high levels (>1000 ρmol/L) are measured. Carmel and 
Agrawal estimate failure rates (false-normal cobalamin levels) 
are between 22% and 35% [26].
Pernicious anemia was self-reported in questionnaires by 11 
participants (0.5%); of whom, none had a serum vitamin B12 
measurement that was in the deficient range (<156 ρmol/L). 
This was despite that only three participants with pernicious 
anemia also reported using vitamin B12 supplement. One 
limitation of the current study is that anti-intrinsic factor 
antibodies were not measured, so it is not possible to estimate 
the actual number that may have false-normal results due to 
interference by anti-intrinsic factor antibodies in the serum, 
though this number is likely to be small.
Twenty-six percent of participants who did not use supplements 
had a serum vitamin B12 measurement in the subclinical 
low-normal range. This is the first assessment of subclinical 
low-normal serum vitamin B12 levels in a large random sample of 
the adult Australian population. Flood et al. similarly reported a 
high prevalence of subclinical low-normal serum vitamin B12 levels, 
though their study was restricted to those aged over 50 years. 
Our findings demonstrate that a high prevalence in subclinical 
low-normal serum vitamin B12 levels (156-250 ρmol/L) is common 
in adults in Australia, and not confined to older people.
Vitamin B12 levels were lower in men and declined with 
increasing age in males but not in females. The median of 
serum vitamin B12 levels in men aged 80 years or older was 
in the subclinical low-normal range. As low vitamin B12 levels 
has been associated with cognitive impairment and AD [1,3], 
Table 2: The prevalence of deficiency and subclinical low-normal serum vitamin B12 levels in over-50 year olds
Country Australia Australia [10] USA [20] Israel [21] Finland [22] Canada [23] The Netherlands [24]
Year This studya 2006 2000 2003 2007 2002 1998
Age range (years) >50 >50 50-83 >65 65-100 >65 74-80
Number of participants 1237 2901 2015 1271 1048 240 105
Reference limit for 
deficiency (ρmol/L)
<156 <125 <148 <147 <150 <165 <150
% Deficient 6.9 6.3 8.8 7.8 6.1 15.3 24.8
Low-normal range (ρmol/L) 156-250 125-220 148-258 - 150-250 165-250 150-260
% Low-normal 30.2 29.0 30.5 - 31.9 24.0 35.3
Design Cross-sectional 
study
Cross-sectional 
study
Cross-sectional 
study
Cross-sectional 
study
Cross-sectional 
study
Cross-sectional 
study
Cross-sectional
study
Setting Community Community Community Community, 
day centers and 
aged care homes
Community Community Community
Instrument for measuring 
B12 level
Roche 
analyzer
Beckman-
access 
analyzer
Biorad 
quanta-
phase II
Baxter 
fluorometric
AutoDelfia Beckman DXI 
analyzer
Dualcount solid 
phase
Method of assay Competitive-
binding
Competitive-
binding
Competitive-
binding
Competitive-
binding
Competitive-
binding
Competitive-
binding
Competitive-
binding
aA sub-sample of the cohort are shown here for comparison to other published studies in over-50 year olds, excludes results on 973 participants 
aged<50 years
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dietary intervention studies should be considered in those with 
declining levels. Men and women were recruited at different 
times, therefore there is potential for assay shifts (for instance, 
due to lot-to-lot reagent shifts) to influence results.
In clinical trials, vitamin B12 supplementation has been shown 
to improve cognition only in those already experiencing 
deficiency [27]. If vitamin B12 deficiency or subclinical 
low-normal levels play a role in cognitive decline, then 
prophylaxis may be more effective than vitamin B12 
replacement after irreversible neuronal damage has occurred. 
Intervention for those with low levels (156-250 ρmol/L) may 
need to be started early at a time when cognition is normal, 
then continued for many years or decades to see an effect. 
Such long-term studies of supplementation have not been 
carried out.
Vitamin B12 supplements are effective in raising serum 
vitamin B12 levels [11], our data confirms supplements that 
are available commercially (including low-dose formulations) 
may be effective since there were no supplement users who 
were deficient. Supplements should be considered for those 
with declining vitamin B12 levels where dietary intervention has 
been ineffective or is inappropriate. Vitamin B12 replacement 
therapy is safe and effective by way of injection or oral 
preparations [28].
The vitamins in cognitive clinical trial, which included 
266 participants followed for 2 years, reported that 
homocysteine-lowering B-vitamins (0.8 mg folic acid, 0.5 mg 
vitamin B12, and 20 mg vitamin B6) slowed progression of cognitive 
decline [29]. These findings offer hope that supplementation 
may be effective in preserving cognitive function.
Vitamin B12 deficiency and subclinical low-normal levels are 
common in a representative Australian adult population, are lower 
in men, decline with age, and improve with supplementation. 
Vitamin B12 levels are readily assayed, and supplementation 
is inexpensive and readily available. Associations between 
low-vitamin B12 levels and many disease states exist, including 
AD and other neurodegenerative diseases. Associations 
between low-vitamin B12 levels also exist with commonly used 
medications, such as PPIs or metformin. Further study to gauge 
the effects of early or prophylactic supplementation in these 
areas will be important given the prevalences of each of these 
associations in the ageing population.
ACKNOWLEDGMENTS
The study investigators would like to extend their thanks to 
current and past staff of the clinical trials unit (The Geelong 
Hospital), for recruiting the cohort, and also to the study 
participants for sharing their time and information.
The GOS was supported by funding from the Victorian Health 
Promotion Foundation (ID 91–0095); the National Medical 
Research Council (ID 251638, ID 299831, ID 628582); the 
Geelong Region Medical Research Foundation; Barwon Health, 
Perpetual Trustees; the Dairy Research and Development 
Corporation; the University of Melbourne; the Ronald Geoffrey 
Arnott Foundation; ANZ Charitable Trust; the American 
Society for Bone and Mineral Research, and Amgen (Europe) 
GmBH. The B12 measurements were supported by the special 
purpose funds of the Alfred Pathology Service. The study 
financial sponsors did not play any role in the design, execution, 
analysis and interpretation of data, or writing, editing or decision 
to publish the manuscript.
REFERENCES
1. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, 
vitamin B12, and serum total homocysteine levels in confirmed 
Alzheimer disease. Arch Neurol 1998;55:1449-55.
2. Triantafyllou NI, Nikolaou C, Boufidou F, Angelopoulos E, 
Rentzos M, Kararizou E, et al. Folate and vitamin B12 levels in 
levodopa-treated Parkinson’s disease patients: their relationship 
to clinical manifestations, mood and cognition. Parkinsonism Relat 
Disord 2008;14:321-5.
3. Köseoglu E, Karaman Y. Relations between homocysteine, folate 
and vitamin B12 in vascular dementia and in Alzheimer disease. Clin 
Biochem 2007;40:859-63.
4. Carmel R. Biomarkers of cobalamin (vitamin B-12) status in the 
epidemiologic setting: A critical overview of context, applications, 
and performance characteristics of cobalamin, methylmalonic acid, 
and holotranscobalamin II. Am J Clin Nutr 2011;94:348S-5.
5. Metz J, Bell AH, Flicker L, Bottiglieri T, Ibrahim J, Seal E, et al. The 
significance of subnormal serum vitamin B12 concentration in older 
people: a case control study. J Am Geriatr Soc 1996;44:1355-61.
6. Vogiatzoglou A, Refsum H, Johnston C, Smith SM, Bradley KM, de 
Jager C, et al. Vitamin B12 status and rate of brain volume loss in 
community-dwelling elderly. Neurology 2008;71:826-32.
7. Andrès E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, 
et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 
2004;171:251-9.
8. Valuck RJ, Ruscin JM. A case-control study on adverse effects: 
H2 blocker or proton pump inhibitor use and risk of vitamin B12 
deficiency in older adults. J Clin Epidemiol 2004;57:422-8.
9. Adams JF, Clark JS, Ireland JT, Kesson CM, Watson WS. Malabsorption 
of vitamin B12 and intrinsic factor secretion during biguanide therapy. 
Diabetologia 1983;24:16-8.
10. Flood VM, Smith WT, Webb KL, Rochtchina E, Anderson VE, 
Mitchell P. Prevalence of low serum folate and vitamin B12 in an 
older Australian population. Aust N Z J Public Health 2006;30:38-41.
11. Flicker L, Vasikaran SD, Thomas J, Acres JM, Norman P, Jamrozik K, 
et al. Efficacy of B vitamins in lowering homocysteine in 
older men: maximal effects for those with B12 deficiency and 
hyperhomocysteinemia. Stroke 2006;37:547-9.
12. Flicker LA, Vasikaran SD, Thomas J, Acres JG, Norman PE, Jamrozik K, 
et al. Homocysteine and vitamin status in older people in Perth. Med 
J Aust 2004;180:539-40.
13. Moore EM, Ames D, Mander AG, Carne RP, Brodaty H, Woodward MC, 
et al. Among vitamin B12 deficient older people, high folate levels 
are associated with worse cognitive function: Combined data from 
three cohorts. J Alzheimers Dis 2014;39:661-8.
14. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, 
et al. Increased risk of cognitive impairment in patients with diabetes 
is associated with metformin. Diabetes Care 2013;36:2981-7.
15. Pasco JA, Nicholson GC, Kotowicz MA. Cohort profile: Geelong 
Osteoporosis Study. Int J Epidemiol 2012;41:1565-75.
16. Henry MJ, Pasco JA, Pocock NA, Nicholson GC, Kotowicz MA. 
Reference ranges for bone densitometers adopted Australia-wide: 
Geelong osteoporosis study. Australas Radiol 2004;48:473-5.
17. Henry MJ, Pasco JA, Korn S, Gibson JE, Kotowicz MA, Nicholson GC. 
Bone mineral density reference ranges for Australian men: Geelong 
Osteoporosis Study. Osteoporos Int 2010;21:909-17.
18. Tucker KL, Rich S, Rosenberg I, Jacques P, Dallal G, Wilson PW, et al. 
Plasma vitamin B-12 concentrations relate to intake source in the 
Framingham Offspring study. Am J Clin Nutr 2000;71:514-22.
19. Australian Bureau of Statistics. Census of Population and Housing: 
Basic Community Profile, 2006. Canberra; 2007. Available from: 
100  J Invest Biochem ● 2014 ● Vol 3 ● Issue 3
Moore, et al.: Vitamin B12 defi ciency in Australia
http://www.abs.gov.au/websitedbs/censushome.nsf/home/
communityprofiles. [Last accessed on 2013 Jan 15]
20. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. 
Arch Intern Med 1996;156:1097-100.
21. Figlin E, Chetrit A, Shahar A, Shpilberg O, Zivelin A, Rosenberg N, 
et al. High prevalences of vitamin B12 and folic acid deficiency in 
elderly subjects in Israel. Br J Haematol 2003;123:696-701.
22. Loikas S, Koskinen P, Irjala K, Löppönen M, Isoaho R, Kivelä SL, et al. 
Vitamin B12 deficiency in the aged: a population-based study. Age 
Ageing 2007;36:177-83.
23. Garcia A, Paris-Pombo A, Evans L, Day A, Freedman M. Is low-dose 
oral cobalamin enough to normalize cobalamin function in older 
people? J Am Geriatr Soc 2002;50:1401-4.
24. van Asselt DZ, de Groot LC, van Staveren WA, Blom HJ, Wevers RA, 
Biemond I, et al. Role of cobalamin intake and atrophic gastritis in 
mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr 
1998;68:328-34.
25. Yang DT, Cook RJ. Spurious elevations of vitamin B12 with pernicious 
anemia. N Engl J Med 2012;366:1742-3.
26. Carmel R, Agrawal YP. Failures of cobalamin assays in pernicious 
anemia. N Engl J Med 2012;367:385-6.
27. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive 
functions after cobalamin/folate supplementation in elderly patients 
with dementia and elevated plasma homocysteine. Int J Geriatr 
Psychiatry 2001;16:609-14.
© GESDAV; licensee GESDAV. This is an open access article licensed 
under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0/) which permits 
unrestricted, non-commercial use, distribution and reproduction in any 
medium, provided the work is properly cited.
Source of Support: The GOS was supported by funding from the 
Victorian Health Promotion Foundation (ID 91–0095); the National Medical 
Research Council (ID 251638, ID 299831, ID 628582); the Geelong Region 
Medical Research Foundation; Barwon Health, Perpetual Trustees; 
the Dairy Research and Development Corporation; the University of 
Melbourne; the Ronald Geoffrey Arnott Foundation; ANZ Charitable 
Trust; the American Society for Bone and Mineral Research, and Amgen 
(Europe) GmBH. The B12 measurements were supported by the special 
purpose funds of the Alfred Pathology Service, Confl ict of Interest: 
None declared.
28. Lane LA, Rojas-Fernandez C. Treatment of vitamin b (12)-deficiency 
anemia: oral versus parenteral therapy. Ann Pharmacother 
2002;36:1268-72.
29. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and 
clinical outcomes of homocysteine-lowering B-vitamin treatment in 
mild cognitive impairment: a randomized controlled trial. Int J Geriatr 
Psychiatry 2012;27:592-600 .
